Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 5, 2006, Pages 413-415

  Grizelj, Ruža ^a   Vuković, Jurica ^a   Filipović Grčić, Boris ^a   Šarić, Dalibor ^a   Luetić, Tomislav ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Aminocaproic acid; Fibrinolysis; Life threatening hemorrhage; Neonate; Recombinant activated factor VII

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ABSENCE OF SIDE EFFECTS; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CASE REPORT; CONGENITAL HEART DISEASE; FIBRINOLYSIS; HEART SURGERY; HUMAN; ILEOSTOMY; INTESTINAL BLEEDING; LUNG HEMORRHAGE; MECONIUM ASPIRATION; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN INTENSIVE CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SURGICAL PATIENT; TREATMENT OUTCOME;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; FACTOR VII; FACTOR VIIA; HEMORRHAGE; HUMANS; INFANT, NEWBORN; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS;

EID: 33745380789     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000233373.71970.6f     Document Type: Article

References (13)

1. Veldman A, Fischer D, Voigt B, Beyer PA, Schlosser R, Allendorf A, et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 2002; 28:1635-1637.
2. Leibovitch L, Kenet G, Mazor K, Matok I, Vardi A, Barzilay Z, et al. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med 2003; 4:444-446.
3. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1):S107-S111.
4. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-14484.
5. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Art Thromb 1992; 12:1111-1121.
6. Giesen PLA, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96:2311-2315.
7. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 2003; 10:797-811.
8. Carr ME Jr, Martin EJ, Kuhn JG, Seremetis SV. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 2003; 89:803-811.
9. Sukhanov VA, Bauman NN, Levit AL. Hyperfibrinolysis: its express diagnosis and role in the development of haemorrhagic syndrome after cardiopulmonary bypass. Cor Vasa 1988; 30:442-446.
10. Ozier Y, Steib A, Ickx B, Nathan N, Derlon A, Guay J, et al. Haemostatic disorders during liver transplantation. Eur J Anaesthesiol 2001; 18:208-218.
11. Reiss RF. Hemostatic defects in massive transfusion: rapid diagnosis and management. Am J Crit Care 2000; 9:158-165.
12. He S, Blomback M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1:1215-1219.
13. Markiewicz M, Kalicinski P, Kaminski A, Laniewski P, Ismail H, Drewniak T, et al. Acute coagulopathy after reperfusion of the liver graft in children: correction with recombinant activated factor VII. Transplant Proc 2003; 35:2318-2319.